Last reviewed · How we verify
NCT06943053: Wound coverage
Evaluation of Ioband Coverage Waterproof Dressing Versus Isolated Waterproof Dressing After Primary Total Knee Arthroplasty
NA trial testing Isolate waterproof dressing (Opsite) in Postoperative Wound Care After TKA in 96 participants. Currently enrolling.
6 April 2026
Quick facts
| Lead sponsor | Thammasat University Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 96 |
| Start date | 6 April 2025 |
| Primary completion | 6 April 2026 |
| Estimated completion | 16 April 2026 |
| Sites | 2 locations across Thailand |
Drugs / interventions tested
- Isolate waterproof dressing (Opsite)
- Ioban coverage group
Conditions studied
- Postoperative Wound Care After TKA — all drugs for Postoperative Wound Care After TKA →
Sponsor
Thammasat University Hospital
Who can join
55 and older, any sex, with Postoperative Wound Care After TKA. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Title: Evaluation of Ioband® Coverage Waterproof Dressing in Post-Operative Total Knee Arthroplasty (TKA) Goal: To evaluate the effectiveness of Ioband® coverage waterproof dressing compared to standard waterproof dressing in reducing dressing change frequency and peel-off degree post-op TKA. Main Research Questions: 1. Does Ioband® coverage waterproof dressing significantly decrease the degree of peel-off compared to standard waterproof dressing? 2. Does Ioband® coverage reduce the number of wound dressing changes required post-operatively? 3. Does Ioband® coverage improve overall patient satisfaction compared to standard waterproof dressing? Participants: Participants will include patients who have undergone total knee arthroplasty (TKA). Main Tasks and Interventions: 1. Randomization: Participants will be randomly assigned to receive either the Ioband® coverage waterproof dressing or the standard waterproof dressing. 2. Application of Dressings: Participants will have the assigned dressing applied to their surgical site post-operatively. 3. Assessment of Peel-Off Degree: Participants will undergo assessments to evaluate the degree of peel-off of the dressing over a specified time. 4. Wound Dressing Changes: Participants will have their dressing changed as per routine care protocols, with documentation of the number of changes. 5. Patient Satisfaction Survey: Participants will complete a satisfaction survey to assess their experiences with the dressing and overall comfort. Conclusion: The trial aims to provide insights into the benefits of Ioband® coverage waterproof dressing in improving post-operative care for TKA patients, focusing on key outcomes related to dressing performance and patient satisfaction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06943053
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Thammasat University Hospital trials
Trials by the same sponsor.
- NCT06910930 — Impact of Muscle Training Device on Non-Severe OSA · NA · recruiting
- NCT06800846 — Comparative Analgesic Effect After Total Knee Arthroplasty Between Intraosseous and Peri-articular Injection · Phase 4 · enrolling by invitation
- NCT06328062 — Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA · NA · recruiting
- NCT06323577 — Comparing Efficacy Between Restricted Kinematic Alignment vs Mechanical Alignment in Bilateral TKA · NA · recruiting
- NCT06312527 — Mepiform in Simultaneous Bilateral TKA · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06943053 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thammasat University Hospital
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06943053.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing